Evaluating Upadacitinib for Ulcerative Colitis in Chinese Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness and safety of upadacitinib in treating moderate to severely active ulcerative colitis (UC) among Chinese adult participants. Approximately 80 adults who have been prescribed upadacitinib by their physicians will be enrolled and followed for up to one year. The treatment will be administered according to local marketing authorization, and participants will attend regular visits for routine data collection without any additional burden compared to their standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Chinese participants meet the diagnosis of moderately to severely active Ulcerative colitis (UC)
* Participants prescribed upadacitinib at discretion of their treating physicians based on sufficient consideration of benefits/risks for patients per local label
* Participant must be an adult (≥ 18 years)
* Participant must provide written authorization to use personal and/or health data prior to the entry into the study

Exclusion Criteria:

* Participant participating in any interventional trials
* Participant with any contraindication to upadacitinib as listed on the local China label
* Participant unwilling or unable to comply with the study requirements, including completion of patient reported outcome questionnaires

Where it's running

• The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997
  Guangzhou, Guangdong, China Recruiting
• The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753
  Guangzhou, Guangdong, China Recruiting
• The Second Affiliated Hospital Of Zhengzhou University /ID# 274754
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Yuting Xie
• Email: yuting.xie@abbvie.com

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Assessing Upadacitinib Treatment in Adults with Inflammatory Bowel Disease in Belgium

  This study is testing how well the medication upadacitinib works and how safe it is for adults with moderate to severe ulcerative colitis and Crohn's disease in Belgium over three years.

  Recruiting at 11 sites AbbVie · Bonheiden, Antwerpen and 10 other locations · NCT06581042

• Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy

  This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.

  Recruiting at 5 sites Austin Health · Hobart and 6 other locations · NCT07916727

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.